Barbara Seliger

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. doi request reprint The future of immune checkpoint therapy
    Padmanee Sharma
    Department of Immunology, M D Anderson Cancer Center, Houston, TX, USA Genitourinary Medical Oncology, M D Anderson Cancer Center, Houston, TX, USA
    Science 348:56-61. 2015
  2. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
  3. doi request reprint Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF
    Padmanee Sharma
    Department of Genitourinary Medical Oncology, M D Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
    J Immunother 31:849-57. 2008
  4. ncbi request reprint Immunotherapeutic strategies for high-risk bladder cancer
    Padmanee Sharma
    Department of Genitourinary Medical Oncology and Immunology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 34:165-72. 2007
  5. ncbi request reprint Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma
    Padmanee Sharma
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 12:5442-7. 2006
  6. pmc CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma
    Padmanee Sharma
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 104:3967-72. 2007
  7. pmc Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues
    Hong Chen
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 106:2729-34. 2009
  8. pmc Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial
    Bradley C Carthon
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 16:2861-71. 2010
  9. pmc Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
    Padmanee Sharma
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Box 0018 7, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Nat Rev Cancer 11:805-12. 2011
  10. pmc CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
    Chrysoula I Liakou
    Department of Genitourinary Medical Oncology, M D Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 105:14987-92. 2008

Collaborators

  • Padmanee Sharma
  • Lloyd J Old
  • Achim A Jungbluth
  • Dean F Bajorin
  • James P Allison
  • Christopher Logothetis
  • Yu Shen
  • H W Herr
  • V E Reuter
  • Elizabeth A Mittendorf
  • John F Ward
  • Hong Chen
  • Sacha Gnjatic
  • J D Wolchok
  • A N Houghton
  • Guido Dalbagni
  • James Eastham
  • Sherri Machele Donat
  • Yao Tseng Chen
  • Jingjing Sun
  • Derek Ng Tang
  • Chrysoula I Liakou
  • Aimee E Hammerstrom
  • Bernard A Fox
  • Bradley C Carthon
  • Ashish Kamat
  • Patricia Troncoso
  • Xingxing Zang
  • Tihui Fu
  • Tara Withington
  • Jonathan L Bramson
  • Rik J Scheper
  • Marij Jp Welters
  • Ulrich Keilholtz
  • Michele Guida
  • Robert Rees
  • Jens Peter Marschner
  • Kunle Odunsi
  • Leif Hakansson
  • Patrick Hwu
  • Elizabeth M Jaffee
  • Laurence Zitvogel
  • Cristina Maccalli
  • Michael T Lotze
  • Mary L Disis
  • Licia Rivoltini
  • Ena Wang
  • Alfred E Chang
  • Pedro J Romero
  • Per thor Straten
  • Giorgio Parmiani
  • Tanja de Gruijl
  • Bradley J Atkinson
  • Zhigang Tian
  • Rolf Kiessling
  • Michael I Nishimura
  • Cedrik M Britten
  • Rejean Lapointe
  • Axel Hoos
  • Heinz Zwierzina
  • Christian Ottensmeier
  • Sylvia Janetzki
  • Michael Papamichail
  • William J Murphy
  • Howard L Kaufman
  • Ronald B Herberman
  • Pawel Kalinski
  • Hyam I Levitsky
  • Ignacio Melero
  • Steinar Aamdal
  • James H Finke
  • Cornelius Melief
  • Antoni Ribas
  • Lindy G Durrant
  • Jirina Bartunkova
  • Francesco M Marincola
  • Dainius Characiejus
  • Giuseppe Masucci
  • Shukui Qin
  • Beatrix Kotlan
  • Jill O'Donnell-Tormey
  • Hauke Winter
  • Jared A Gollob
  • Hideaki Tahara
  • Xuetao Cao
  • Weihua Xiao
  • Michele Maio
  • Robert O Dillman
  • Diana H Cauley
  • Sjoerd H van der Burg

Detail Information

Publications17

  1. doi request reprint The future of immune checkpoint therapy
    Padmanee Sharma
    Department of Immunology, M D Anderson Cancer Center, Houston, TX, USA Genitourinary Medical Oncology, M D Anderson Cancer Center, Houston, TX, USA
    Science 348:56-61. 2015
    ....
  2. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
    ..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer...
  3. doi request reprint Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF
    Padmanee Sharma
    Department of Genitourinary Medical Oncology, M D Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
    J Immunother 31:849-57. 2008
    ..Induction of higher frequency of CD8 T-cell responses may be possible in clinical trials implementing NY-ESO-1 vaccination in combination with other immunomodulatory agents...
  4. ncbi request reprint Immunotherapeutic strategies for high-risk bladder cancer
    Padmanee Sharma
    Department of Genitourinary Medical Oncology and Immunology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 34:165-72. 2007
    ..In this review, we discuss the complexity of the immune system and therapies that are considered capable of manipulating it to potentially benefit patients with bladder cancer...
  5. ncbi request reprint Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma
    Padmanee Sharma
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 12:5442-7. 2006
    ..These antigens were evaluated for both the degree of expression and prognostic value in cancer of the urothelium...
  6. pmc CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma
    Padmanee Sharma
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 104:3967-72. 2007
    ..001) and overall survival (P = 0.018) than did patients with similar-staged UC and fewer intratumoral CD8 TILs. We conclude that the extent of intratumoral CD8 TILs is an important prognostic indicator in advanced UC...
  7. pmc Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues
    Hong Chen
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 106:2729-34. 2009
    ..These data should be taken into consideration for evaluation of efficacy as well as immune-related adverse events associated with anti-CTLA-4 therapy...
  8. pmc Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial
    Bradley C Carthon
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 16:2861-71. 2010
    ..Our group conducted the first preoperative clinical trial with the anti-CTLA-4 antibody ipilimumab in 12 patients with localized urothelial carcinoma of the bladder...
  9. pmc Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
    Padmanee Sharma
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Box 0018 7, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Nat Rev Cancer 11:805-12. 2011
    ....
  10. pmc CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
    Chrysoula I Liakou
    Department of Genitourinary Medical Oncology, M D Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 105:14987-92. 2008
    ....
  11. pmc Cancer immunotherapy: sipuleucel-T and beyond
    Aimee E Hammerstrom
    Division of Pharmacy, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Pharmacotherapy 31:813-28. 2011
    ..Additional studies will determine how these therapies can best improve clinical outcomes in patients with cancer...
  12. doi request reprint Identification of human regulatory T cells in the setting of T-cell activation and anti-CTLA-4 immunotherapy on the basis of expression of latency-associated peptide
    Jingjing Sun
    Departments of Genitourinary Medical Oncology and Immunology, The University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Discov 2:122-30. 2012
    ..Therefore, we propose that LAP should be used as a marker of Tregs for immune monitoring studies in patients treated with active immunotherapy such as anti-CTLA-4...
  13. doi request reprint Mechanisms of T-cell inhibition: implications for cancer immunotherapy
    Elizabeth A Mittendorf
    Department of Surgical Oncology, Unit 444, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Expert Rev Vaccines 9:89-105. 2010
    ..In this review, we discuss several regulatory mechanisms that act to control effector T-cell responses and identify strategies to circumvent these mechanisms in order to improve clinical responses...
  14. pmc Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer
    Chrysoula I Liakou
    Department of Genitourinary Medical Oncology, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Immun 7:10. 2007
    ..This review will focus on immunological responses to bladder cancer and ongoing studies to identify factors that are amenable to therapeutic manipulation...
  15. pmc Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy
    Jingjing Sun
    Department of Genitourinary Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX, USA
    Cancer Immun 8:9. 2008
    ..We propose that decreased levels of IL-10 after treatment with anti-CTLA-4 therapy may be responsible for irAEs in some patients and needs to be further investigated in larger studies...
  16. ncbi request reprint Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer
    Padmanee Sharma
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 3:19. 2003
    ..This patient's T-cell response was determined to be specific for a new NY-ESO-1 epitope, p94-102, in the context of HLA-B35...
  17. pmc B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome
    Xingxing Zang
    Howard Hughes Medical Institute, Immunology Program and Ludwig Center for Cancer Immunotherapy, and Departments of Surgery and Urology, Pathology, and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 104:19458-63. 2007
    ..Given the proposed immune-inhibitory mechanisms of B7-H3 and B7x, these molecules represent attractive targets for therapeutic manipulation in prostate cancer...